There is no single test for dementia. Diagnosis involves a combination of cognitive screening, physical examination, brain imaging, blood work, and sometimes advanced biomarker testing. The process typically unfolds over several visits, starting with your primary care doctor and often continuing with a neurologist or neuropsychologist who specializes in cognitive disorders.
Cognitive Screening Tests
The first step is usually a brief cognitive screening test done in the office. The two most common are the Mini-Mental State Exam (MMSE) and the Montreal Cognitive Assessment (MoCA), both scored on a 30-point scale. On the MMSE, scores between 24 and 30 are considered normal. On the MoCA, scores of 17 or above capture the range where mild cognitive impairment is likely, while people with Alzheimer’s dementia average around 15. These tests ask you to recall words, draw shapes, name animals, count backward, and follow multi-step instructions. They take about 10 to 15 minutes.
The MoCA was specifically designed to catch milder problems that the MMSE can miss, particularly in areas like planning, organization, and abstract thinking. If your screening score raises concern, you’ll likely be referred for a full neuropsychological evaluation, which is a longer battery of tests (often two to four hours) that measures memory, attention, language, problem-solving, and spatial reasoning in much greater detail. This detailed testing helps doctors identify exactly which cognitive abilities are affected, which matters because different types of dementia damage different parts of the brain in distinct patterns.
Medical History and Informant Interviews
Your doctor will review your full medical history, including medications, past head injuries, alcohol use, and family history of dementia. Just as important, someone close to you, a spouse, adult child, or close friend, will typically be asked about the changes they’ve observed. This informant interview is a critical piece of the puzzle because people in the early stages of dementia often underestimate their own difficulties. In depression, the opposite tends to happen: people describe their memory as worse than it actually tests.
Neurological and Physical Examination
A neurological exam checks your reflexes, muscle strength, coordination, eye movements, speech, and sensation. Your doctor will watch you walk, looking for specific patterns that point toward different conditions. Shortened strides, reduced arm swing, and a tendency to fall backward when gently pulled suggest a parkinsonian disorder like Lewy body dementia. A wide, unsteady gait with lurching steps points toward problems in the brain’s coordination centers. Balance, posture, and how easily you shift between tasks all provide physical clues that complement the cognitive testing.
Blood Tests to Rule Out Treatable Causes
Before diagnosing a neurodegenerative disease, doctors need to rule out conditions that can mimic dementia but are actually reversible. Standard blood work typically checks for vitamin B12 deficiency, thyroid problems (both overactive and underactive), and basic metabolic abnormalities. Folate, vitamin B1, and vitamin E levels may also be checked. Low B12 alone can cause significant memory problems and confusion that improve with treatment.
Depending on your history, doctors might test for liver or kidney dysfunction, infections like HIV or syphilis, or even heavy metal exposure. Certain medications, especially sedatives, anticholinergic drugs, and some combinations of prescriptions, can also cause cognitive impairment that clears up once the medication is adjusted. These treatable causes account for a meaningful percentage of people who come in worried about dementia, which is why this step matters so much.
Distinguishing Dementia From Depression
Depression and dementia can look remarkably similar, especially in older adults. Both can cause poor concentration, slowed thinking, and memory complaints. Doctors use several clinical clues to tell them apart. Depression typically has a more sudden onset, while dementia develops gradually over months or years. In depression, memory performance actually improves when the person is given hints or cues during testing. In Alzheimer’s, cues don’t help much. People with depression tend to give up easily on harder test questions, often answering “I don’t know,” while those with dementia usually keep trying but get answers wrong.
Language problems, difficulty recognizing objects, and trouble performing familiar physical tasks like buttoning a shirt are hallmarks of progressing dementia and are uncommon in depression alone. Apathy without sadness is also more characteristic of dementia, while depression usually involves a clearly low mood. Since depression and dementia can also coexist, a psychiatric evaluation may be part of the workup.
Brain Imaging
Most people undergoing a dementia evaluation will get at least one brain scan. A CT scan can quickly identify structural problems like tumors, strokes, fluid buildup (normal pressure hydrocephalus), or bleeding that could explain cognitive symptoms. MRI provides much more detail and is the preferred imaging tool when available.
On MRI, doctors look for shrinkage in specific brain regions. In Alzheimer’s disease, the hippocampus, the brain’s memory center located deep in the temporal lobe, shrinks early and measurably. Trained radiologists can rate this shrinkage on visual scales that reliably distinguish people whose mild cognitive impairment will progress to Alzheimer’s from those who will remain stable. Thinning of the brain’s outer layer in temporal and frontal regions is another marker, and it appears even before significant volume loss in early stages. Different patterns of shrinkage help distinguish Alzheimer’s from frontotemporal dementia, vascular dementia, and other types.
PET scans, which show brain activity or specific protein deposits, are sometimes used in specialized centers. An amyloid PET scan can reveal whether the hallmark protein plaques of Alzheimer’s disease are present in the brain, which helps confirm or rule out the diagnosis when other testing is inconclusive.
Advanced Biomarker Testing
For cases where the diagnosis is uncertain, doctors can measure proteins in cerebrospinal fluid (CSF) collected through a lumbar puncture. The key markers are a protein fragment called amyloid beta 1-42, which drops in the spinal fluid when it’s accumulating in the brain as plaques, and tau proteins, which rise as brain cells are damaged. The ratio between tau and amyloid is a particularly robust indicator of Alzheimer’s pathology, performing better than either marker alone.
A major recent development is blood-based testing. In May 2025, the FDA cleared the first blood test to aid in diagnosing Alzheimer’s disease. The test measures the ratio of two proteins (pTau217 and beta-amyloid 1-42) in a standard blood draw. In clinical studies of 499 cognitively impaired adults, 91.7% of people who tested positive actually had amyloid plaques confirmed by PET scan or spinal fluid testing, and 97.3% of those who tested negative were truly negative. This blood test can reduce the need for PET scans or spinal taps, though it is not a standalone diagnostic tool and is currently intended for use in specialty settings for patients aged 55 and older who are already showing cognitive symptoms.
Functional Assessment
A key part of the diagnostic criteria for dementia, as distinct from mild cognitive impairment, is whether cognitive problems have started interfering with your ability to function independently. Doctors assess this through standardized scales and through conversations with you and your family. Basic daily activities include bathing, dressing, eating, and using the toilet. More complex tasks, called instrumental activities, include managing finances, taking medications correctly, cooking, shopping, and using transportation.
The Lawton scale, one of the most commonly used tools, scores independence in these complex tasks from 0 (fully dependent) to 8 (fully independent). A person who still scores well on these functional measures but shows clear cognitive decline on testing may be diagnosed with mild cognitive impairment rather than dementia. The distinction matters because it affects treatment planning, legal considerations, and what kind of support you might need going forward.
How the Pieces Come Together
No single result drives the diagnosis. Doctors synthesize everything: which cognitive abilities are impaired and how severely, whether daily functioning is affected, what the brain scans show, whether reversible causes have been excluded, and what the pattern of onset and progression looks like. Current diagnostic standards require a significant decline in at least one cognitive domain, such as memory, executive function, language, or visuospatial ability, that represents a clear drop from a person’s previous level. The specific combination of impaired domains, physical findings, and imaging patterns is what points toward a particular type of dementia.
The full process, from initial screening to a confident diagnosis, can take weeks to a few months, depending on how many specialists and tests are involved. Some academic medical centers have dedicated memory clinics where much of this evaluation happens in a coordinated fashion over one or two visits.